KR0158049B1 - Novel bifidobacterium longum hspo which produce polysaccharide - Google Patents
Novel bifidobacterium longum hspo which produce polysaccharideInfo
- Publication number
- KR0158049B1 KR0158049B1 KR1019950027604A KR19950027604A KR0158049B1 KR 0158049 B1 KR0158049 B1 KR 0158049B1 KR 1019950027604 A KR1019950027604 A KR 1019950027604A KR 19950027604 A KR19950027604 A KR 19950027604A KR 0158049 B1 KR0158049 B1 KR 0158049B1
- Authority
- KR
- South Korea
- Prior art keywords
- bifidobacterium
- fermented milk
- bifidobacterium longum
- viscous
- lactic acid
- Prior art date
Links
- 150000004676 glycans Chemical class 0.000 title claims abstract description 34
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 34
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 34
- 241001608472 Bifidobacterium longum Species 0.000 title claims abstract description 12
- 229940009291 bifidobacterium longum Drugs 0.000 title claims abstract description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 44
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 31
- 241000894006 Bacteria Species 0.000 claims abstract description 23
- 239000004310 lactic acid Substances 0.000 claims abstract description 22
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 22
- 235000015140 cultured milk Nutrition 0.000 claims abstract description 21
- 239000005862 Whey Substances 0.000 claims abstract description 15
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 15
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 15
- 238000000926 separation method Methods 0.000 claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 claims abstract description 10
- 239000002537 cosmetic Substances 0.000 claims abstract description 6
- 230000003020 moisturizing effect Effects 0.000 claims abstract description 6
- 238000000855 fermentation Methods 0.000 claims abstract description 5
- 230000004151 fermentation Effects 0.000 claims abstract description 5
- 230000014759 maintenance of location Effects 0.000 claims abstract description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000000151 deposition Methods 0.000 claims 2
- 210000003608 fece Anatomy 0.000 abstract description 6
- 235000013305 food Nutrition 0.000 abstract description 6
- 239000004909 Moisturizer Substances 0.000 abstract description 4
- 230000001333 moisturizer Effects 0.000 abstract description 4
- 239000003381 stabilizer Substances 0.000 abstract description 4
- 230000008520 organization Effects 0.000 abstract description 2
- 239000002778 food additive Substances 0.000 abstract 1
- 235000013373 food additive Nutrition 0.000 abstract 1
- 239000002609 medium Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 11
- 235000020183 skimmed milk Nutrition 0.000 description 10
- 239000011345 viscous material Substances 0.000 description 10
- 229920001817 Agar Polymers 0.000 description 7
- 239000008272 agar Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 229940041514 candida albicans extract Drugs 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 239000012138 yeast extract Substances 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 108010052764 Fructose-6-phosphate phosphoketolase Proteins 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- 241000589516 Pseudomonas Species 0.000 description 3
- 241000589634 Xanthomonas Species 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- ZHGNHOOVYPHPNJ-UHFFFAOYSA-N Amigdalin Chemical compound FC(F)(F)C(=O)OCC1OC(OCC2OC(OC(C#N)C3=CC=CC=C3)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C2OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C1OC(=O)C(F)(F)F ZHGNHOOVYPHPNJ-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical group O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Diphosphoinositol tetrakisphosphate Chemical compound OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 235000014048 cultured milk product Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940040511 liver extract Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 2
- 238000001612 separation test Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- LXWQKLVAJOMMSN-REOHCLBHSA-N (2s)-2-amino-3-sulfanylpropanoyl chloride Chemical compound SC[C@H](N)C(Cl)=O LXWQKLVAJOMMSN-REOHCLBHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- 241000589158 Agrobacterium Species 0.000 description 1
- 241000186063 Arthrobacter Species 0.000 description 1
- 241000589151 Azotobacter Species 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000588881 Chromobacterium Species 0.000 description 1
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000588698 Erwinia Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000589344 Methylomonas Species 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- -1 ducitol Chemical compound 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940093496 esculin Drugs 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- DCCSDBARQIPTGU-HSZRJFAPSA-N fesoterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(CO)C=2)OC(=O)C(C)C)=CC=CC=C1 DCCSDBARQIPTGU-HSZRJFAPSA-N 0.000 description 1
- 238000005429 filling process Methods 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- WHWDWIHXSPCOKZ-UHFFFAOYSA-N hexahydrofarnesyl acetone Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)=O WHWDWIHXSPCOKZ-UHFFFAOYSA-N 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 1
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- 229940053050 neomycin sulfate Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229960001914 paromomycin Drugs 0.000 description 1
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- RYCLIXPGLDDLTM-UHFFFAOYSA-J tetrapotassium;phosphonato phosphate Chemical compound [K+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])([O-])=O RYCLIXPGLDDLTM-UHFFFAOYSA-J 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/48—Thickener, Thickening system
Abstract
본 발명은 보습성이 우수한 다량의 점질다당류(粘質多糖類)를 생산하는 새로운 유산균인 비피도박테리움 롱검 HS90(Bifidobacterium longum HS90)(기탁기관 : 한국종균협회; 기탁일 : 1995년 7월 26일; 기탁번호 : 제 KFCC10864호)에 관한 것으로, 보다 상세하게는 보습성이 좋은 점질다당류를 생산하여 이를 화장품의 보습제 및 식품의 안정제 등으로 사용할 수 있을 뿐만 아니라, 균주 자체를 발효균주로 사용하여 발효유를 제조할 경우 발효유의 점도를 높여주고 조직을 부드럽게 하므로 유청분리가 없는 농후한 외관(body)의 질좋은 발효유를 얻을 수 있는, 비피도박테리움 속의 유산균인 비피도박테리움 롱검 HS90에 관한 것이다.The present invention is a new lactic acid bacterium, Bifidobacterium longum HS90, which produces a large amount of viscous polysaccharides with excellent moisture retention (Bifidobacterium longum HS90) (Deposit Organization: Korean spawn association; Deposit date: July 1995, 26 (B) No. KFCC10864), more specifically, it can produce a highly moisturizing viscous polysaccharide, which can be used as a moisturizer of cosmetics and a stabilizer of food, and fermented milk using the strain itself as a fermentation strain. When preparing the high viscosity of the fermented milk and soften the tissue to obtain a rich fermented milk without body whey separation (body), Bifidobacterium long gum HS90 is a lactic acid bacteria in the Bifidobacterium.
본 발명의 비피도박테리움 롱검 HS90은 한국 유아의 분변으로부터 분리·동정하여 얻은 것으로, 그 자체를 발효유 생산의 종균으로 사용할 수 있으며, 또한 본 균주가 생산한 점질다당류를 분리하여 식품의 첨가제나 화장품의 보습제로 사용할 수 있다.Bifidobacterium longgum HS90 of the present invention is obtained by separating and identifying from feces of Korean infants, and can be used as a seed for fermented milk production, and by separating the viscous polysaccharides produced by the strain and food additives or cosmetics. Can be used as a moisturizer.
Description
제1도는 탈지유 배양액의 점도를 도시한 그래프.1 is a graph showing the viscosity of skim milk culture broth.
제2도는 탈지유 배양액의 유청분리도를 도시한 그래프.2 is a graph showing the whey separation of skim milk culture.
제3도는 배양 온도에 따른 유청분리도를 도시한 그래프.3 is a graph showing whey separation according to culture temperature.
본 발명은 보습성이 우수한 다량의 점질다당류(粘質多糖類)를 생산하는 새로운 유산균인 비피도박테리움 롱검 HS90(Bifidobacterium longum HS90)(기탁기관 : 한국종균협회; 기탁일 : 1995년 7월 26일; 기탁번호 : 제 KFCC10864호)에 관한 것으로, 보다 상세하게는 보습성이 좋은 점질다당류를 생산하여 이를 화장품의 보습제 및 식품의 안정제 등으로 사용할 수 있을 뿐만 아니라, 균주 자체를 발효균주로 사용하여 발효유를 제조할 경우 발효유의 점도를 높여주고 조직을 부드럽게 하므로 유청분리가 없는 농후한 외관(body)의 질좋은 발효유를 얻을 수 있는, 비피도박테리움 속의 유산균인 비피도박테리움 롱검 HS90에 관한 것이다.The present invention is a new lactic acid bacterium, Bifidobacterium longum HS90, which produces a large amount of viscous polysaccharides with excellent moisture retention (Bifidobacterium longum HS90) (Deposit Organization: Korean spawn association; Deposit date: July 1995, 26 (B) No. KFCC10864), more specifically, it can produce a highly moisturizing viscous polysaccharide, which can be used as a moisturizer of cosmetics and a stabilizer of food, and fermented milk using the strain itself as a fermentation strain. When preparing the high viscosity of the fermented milk and soften the tissue to obtain a rich fermented milk without body whey separation (body), Bifidobacterium long gum HS90 is a lactic acid bacteria in the Bifidobacterium.
미생물이 세포벽밖에 침적시키는 세포외 다당류는 미생물의 종류, 생리적 상태에 따라 다양하며 점성물질의 형태로 배지속에 분비되거나 또는 세포벽이나 막과 연결된 캡슐의 형태로 생산된다. 이러한 미생물이 생산하는 다당류는 생분해성이고 인체에 독성이 없으며, 조건에 따라 겔 형성능, 표면장력 조절능, 물 흡수능, 결착능, 점착능, 윤활능 및 필름형성능 등의 기능을 가지므로 식품, 화장품 및 석유산업 등에 사용되어 왔다.Extracellular polysaccharides, which microorganisms deposit outside the cell wall, vary according to the type and physiological state of the microorganism and are secreted into the medium in the form of viscous substances or produced in the form of capsules connected to the cell wall or membrane. The polysaccharides produced by these microorganisms are biodegradable and nontoxic to humans, and according to the conditions, they have the functions of gel formation, surface tension control, water absorption, binding, adhesion, lubrication, and film formation. And the petroleum industry.
최근, 산업이 급속하게 발전함에 따라 다당류의 용도도 광범위해져 폐기물의 처리제, 난류 억제제, 세정제, 생분해성 소재, 천연 소재, 봉합사, 인공 생체성분, 서방제, 백신 등에 널리 사용되고 있으며, 각종 질병의 예방과 치료에 사용될 수 있는 가능성을 보여주고 있다.In recent years, with the rapid development of the industry, the use of polysaccharides has also become widespread, and is widely used in waste treatment agents, turbulence inhibitors, cleaning agents, biodegradable materials, natural materials, sutures, artificial biological components, sustained-release agents, vaccines, and the like. It shows the possibility of being used for treatment.
지금까지 알려진 다당류 생성 세균으로는 크산토모나스(Xanthomonas), 아그로박테리움(Agrobacterium), 아조토박터(Azotobacter), 바실러스(Bacillus), 슈도모나스(Pseudomonas), 아트로박터(Arthrobacter), 메틸로모나스(Methylomonas), 크로모박테리움(Chromobacterium), 알칼리게네스(Alkaligenes), 스클레로티움(Sclerotium), 어윈니아(Erwinia) 및 젖산균 등이 있으며, 이들이 생산하는 다당류 중 덱스트란, 알지네이트, 크산탄, 겔란(gellan), 플루란(pullulan), 레반(levan) 등만이 산업적으로 이용되고 있다.Polysaccharide producing bacteria known to date include Xanthomonas, Agrobacterium, Azotobacter, Bacillus, Pseudomonas, Arthrobacter, and Methylmonas Methylomonas, Chromobacterium, Alkaligenes, Sclerotium, Erwinia and Lactic Acid Bacteria, among which the polysaccharides produced are dextran, alginate, xanthan, Only gellan, pullulan, levan and the like are used industrially.
이와 같이, 발견된 다당류에 비해 실제 산업적으로 이용되는 다당류의 수가 훨씬 적은 이유는 기존의 다당류가 가지는 우수한 물성 및 물성의 공통성 때문이기도 하지만 용도의 적용과 개발에 많은 연구가 필요하고 그 연구범위가 넓으며, 신규 다당류나 그 생산 미생물의 탐색과 응용·개발에도 상당한 시간과 노력이 필요하기 때문이다.As such, the reason why the number of polysaccharides actually used in industrial industry is much smaller than that of the found polysaccharides is due to the common properties of the existing polysaccharides and their common properties. In addition, the exploration, application and development of new polysaccharides or their producing microorganisms require considerable time and effort.
그동안 보고된 다당류는 생산하는 유산균으로는 스트렙토코커스 써모필러스, 락토바실러스 불가리쿠스, 락토코커스 락티스 서브스페시스 크레모리스(L.lactis subsp.cremoris) 등이 있으며, 이들의 다당류 생산량은 스트렙토코커스 써모필러스 50~350mg/l, 락토바실러스 불가리쿠스가 60~150mg/l, 락토코커스 락티스 서브스페시스 크레모리스가 80~600mg/l로서 유산균에 의한 다당류의 생산량은 크산토모나스나 슈도모나스 속의 세균에 비해 훨씬 적다. 그러나, 크산토모나스나 슈도모나스 등의 세균과는 달리 유산균들은 오래 전부터 발효식품 등에 널리 사용되어 일반적으로 그 안전성이 인정되고 있는 미생물이란 장점이 있다. 따라서, 이러한 유산균의 안전성 때문에 유산균이 생산하는 다당류들은 앞으로 식품, 화장품, 의약 등의 의료분야에 점차 그 이용이 확대될 것으로 전망된다.The lactic acid bacteria reported in the past are produced by Streptococcus thermophilus, Lactobacillus vulgaris, Lactococcus lactis subsp. Cremoris, and their polysaccharide production is Streptococcus thermo Lactobacillus Lactobacillus Bulgaricus is 60-150mg / l, Lactococcus Lactose Subspecs Cremoris is 80-600mg / l, and the production of polysaccharides by lactic acid bacteria is applied to bacteria of Xanthomonas or Pseudomonas. Much less than. However, unlike bacteria such as Xanthomonas and Pseudomonas, lactic acid bacteria have been widely used for fermented foods for a long time and generally have the advantage of being a microorganism whose safety is recognized. Therefore, due to the safety of these lactic acid bacteria, polysaccharides produced by lactic acid bacteria are expected to be gradually used in the medical field, such as food, cosmetics, medicine.
발효유의 견고성을 증진시키기 위하여 종래에는 발효유의 총고형분을 증가시키거나, 발효유에 전분, 카라기난, 구아검, 펙틴, 젤라틴 등을 첨가하거나, 또는 점성물질을 생산하는 유산균을 종균으로 사용하였다. 그러나, 전분이나 카라기난 혹은 펙틴 등과 같은 첨가물은 발효유의 맛, 향, 촉감에 나쁜 영향을 주기 때문에 바람직하지 않으므로 점차 점성물질을 생산하는 유산균주의 사용이 권장되고 있다. 특히, 네덜란드, 프랑스 등에서는 안정제의 첨가가 법적으로 규제되어 있어 점성물질을 생성하는 유산균이 이용되고 있다.In order to enhance the firmness of fermented milk, conventionally, the total solid content of fermented milk is increased, or starch, carrageenan, guar gum, pectin, gelatin, or the like is added to the fermented milk, or lactic acid bacteria that produce viscous materials are used as seed. However, additives such as starch, carrageenan, or pectin are not preferred because they adversely affect the taste, aroma, and feel of fermented milk. Therefore, it is recommended to use lactic acid strains that gradually produce viscous substances. In particular, in the Netherlands and France, the addition of stabilizers is legally regulated, so lactic acid bacteria that produce viscous substances are used.
발효유중의 점성물질은 유산균과 유단백질을 결합시켜 발효유 제품의 큰 결점인 유청 분리현상을 완화시키고, 점성을 증가시키며, 점착성을 증가시켜 요구르트의 물성을 향상시키는 역할을 하게 된다. 따라서, 점성물질을 생산하는 유산균을 이용하여 발효유 제품을 제조할 경우, 조직이 부드럽고 농후하게 됨과 동시에 제조과정중의 펌핑, 브렝딩, 충진공정의 충격, 온도 및 물리적 충격에 대해서도 조직을 유지시켜 주는 장점이 있다.Viscous material in fermented milk combines lactobacillus and milk protein to alleviate whey separation, a major drawback of fermented milk products, increase viscosity and increase adhesiveness, thereby improving yogurt properties. Therefore, when the fermented milk product is manufactured using lactic acid bacteria that produce viscous substances, the tissue becomes soft and thick, and at the same time, it maintains the tissue against the impact of pumping, branding, filling process, temperature and physical impact during the manufacturing process. There is an advantage.
인체 유래 장내 미생물로 그 유용성을 인정받고 있는 비피도박테리아의 경우, 다당류를 거의 생산하지 않거나 일부 생산한다 하더라도 그 생산량이 매우 적어 이용되지 않고 있었다.In the case of Bifidobacteria, which has been recognized for its usefulness as a human-derived intestinal microorganism, even if it produces little or no polysaccharides, its production is not used because it is very small.
이에 본 발명자들은 점성물질을 생산하는 새로운 유산균, 특히 비피도박테리아를 개발하기 위해 연구하던 중, 한국 유아의 분변으로부터 다량의 점질다당류를 생산하는 새로운 비피도박테리움을 분리·동정하는데 성공하게 되었다.Accordingly, the present inventors succeeded in separating and identifying a new Bifidobacterium producing a large amount of viscous polysaccharides from feces of Korean infants while studying to develop a new lactic acid bacterium, particularly a Bifidobacteria, which produces viscous substances.
본 발명은 다량의 점질다당류를 생산하는 새로운 균주인 비피도박테리움 롱검 HS90을 제공하는 것을 목적으로 한다.An object of the present invention is to provide a Bifidobacterium long gum HS90, which produces a large amount of viscous polysaccharides.
또한, 본 발명은 비피도박테리움 롱검 HS90이 생산한 다당류를 분리하여 이를 식품, 화장품, 약품 등에 이용하도록 하는 것을 목적으로 한다.In addition, an object of the present invention is to separate the polysaccharides produced by Bifidobacterium long gum HS90 to use them in food, cosmetics, drugs and the like.
또한, 본 발명은 비피도박테리움 롱검 HS90 자체를 종균으로 사용하여 발효유를 제조함으로써 유청분리 현상이 없는 농후한 외관의 질좋은 발효유를 제공하는 것을 목적으로 한다. 본 발명에 따른 다량의 점질다당류를 생산하는 새로운 유산균인 비피도박테리움 롱검 HS90은 한국 유아의 분변으로부터 분리하여 동정한 비피도박테리움 속의 신균주이다.In addition, an object of the present invention is to provide a fermented milk with a rich appearance without whey separation phenomenon by producing fermented milk using Bifidobacterium long gum HS90 itself as a seed. Bifidobacterium longgum HS90, a novel lactic acid bacterium that produces a large amount of viscous polysaccharides according to the present invention, is a strain of Bifidobacterium spp. Isolated from the feces of Korean infants.
[비피도박테리움 롱검 HS90의 분리·동정][Isolation and Identification of Bifidobacterium Long Gum HS90]
본 균주는 한국 유아의 분변으로부터 분리·동정한 균주이다. 건강한 유아의 분변을 채취 즉시 유동 파라핀이 중층된 말혈액을 첨가하지 않은 비엘(blood-glucose-liver) 액체 배지에 넣어 실험실로 이송하였다. 이 시료를 혐기 희석액으로 연속적으로 희석하여 엔피엔엘(NPNL) 한천 배지에 도말하고 혐기자(Anaerobic jar)에 넣은 후, 이산화탄소로 치환하고 37℃에서 48시간 배양하였다. 배양 결과 생긴 균락으로부터 백금이로 접촉하여 끈적거리는 균락을 점성물질 생산균주로 선발하여 분리하였다. 순수 분리된 균주를 비엘 액체배지에서 37℃로 24시간 동안 배양한 후, 0.2%의 효모 추출물이 함유된 12% 멸균 환원 탈지분유에 재접종하여 37℃에서 24시간 배양한 후 배양액의 점성 유무를 확인하였다.This strain was isolated and identified from feces of Korean infants. The feces of healthy infants were taken immediately to a laboratory in blood-glucose-liver liquid medium without fluid paraffin-layered horse blood. This sample was continuously diluted with an anaerobic dilution solution, plated in NPNL agar medium, and placed in an anaerobic jar, replaced with carbon dioxide, and incubated at 37 ° C. for 48 hours. Sticky colonies were contacted with platinum from the resulting colonies and selected as a viscous-producing strain. After purely isolated strains were incubated for 24 hours at 37 ℃ in Biel liquid medium, and then re-inoculated with 12% sterile reduced skim milk powder containing 0.2% yeast extract and incubated at 37 ℃ for 24 hours and then the viscosity of the culture medium Confirmed.
[비피도박테리움 롱검 HS90의 특성][Characteristics of Bifidobacterium long gum HS90]
본 발명에 사용된 비피도박테리움 롱검 HS90의 특성은 다음과 같다.The properties of the Bifidobacterium long gum HS90 used in the present invention are as follows.
1) 균의 형태1) Morphology
BL 한천평판배지에서 37℃, 2일간 배양했을 때 균의 형태Morphology of the bacteria when incubated at 37 ° C for 2 days in BL agar plate medium
① 세포의 크기 : 1.0~2.5㎛① Cell size: 1.0 ~ 2.5㎛
② 세포의 형상 : 간균, Y자, 곤봉형태② Cell shape: Bacillus, Y-shaped, club
③ 운동성 : 없음③ Mobility: None
④ 포자 형성능 : 없음④ Spore Formability: None
⑤ 그람 염색 : 양성⑤ Gram staining: positive
2) 균총의 형태2) Form of the flora
BL 한천평판배지에서 37℃, 2일간 배양했을 때 균의 형태Morphology of the bacteria when incubated at 37 ° C for 2 days in BL agar plate medium
① 형상 : 원형① Shape: Round
② 크기 : 0.1~0.4㎝(직경)② Size: 0.1 ~ 0.4㎝ (Diameter)
③ 융기 : 볼록③ uplift: convex
④ 색조 : 광택이 나는 황백색④ Tint: Glossy Yellowish White
⑤ 표면 : 원활⑤ surface: smooth
3) 생리적 성질3) Physiological Properties
생육 온도 : 생육 온도 범위 : 25~44℃ 최적 온도 범위 : 35~42℃Growth temperature: Growth temperature range: 25 ~ 44 ℃ Optimum temperature range: 35 ~ 42 ℃
생육 pH : 생육 pH 범위 : 4.5~7.5 최적 pH 범위 : 6.0~7.0Growth pH: Growth pH Range: 4.5 ~ 7.5 Optimum pH Range: 6.0 ~ 7.0
산소의 영향 : 편성 혐기성Effect of Oxygen: Organized Anaerobic
4)카탈리제 : -4) Catalase:-
5) 가스 생성 여부 : -5) Whether gas is generated:-
6) F6PPK(fructose-6-phosphate phosphoketolase) : +6) F6PPK (fructose-6-phosphate phosphoketolase): +
7) 20℃에서 생육 : -7) Growth at 20 ℃:-
8) 45℃에서 생육 : -8) Growth at 45 ℃:-
9) 인돌 생산 : -9) Indole Production:-
10) 유산 생산 : +10) Lactic Acid Production: +
11) 초산 생산 : +11) Acetic acid production: +
12) 당이용성12) Sugar availability
갈락토스 : +Galactose: +
과당 : +Fructose: +
글루코네이트 : -Gluconate:-
글리세롤 : -Glycerol:-
덱스트린 : -Dextrin:-
두시톨 : -Ducitol:-
라피노스 : +Rafinos: +
락툴로스 : +Lactulose: +
람노스 : -Rhamnose:-
리보스 : -Ribose:-
만노스 : ±Mannose: ±
만니톨 : -Mannitol:-
맥아당 : +Maltose: +
멜레지토스 : -Melegitos:-
멜리비오스 : -Melibiose:-
살리신 : +Raised: +
셀로비오스 : -Cellobiose:-
소르보스 : -Sorboth:-
소르비톨 : -Sorbitol:-
아도니톨 : -Adonitol:-
아리비노스 : +Aribinos: +
아미그달린 : -Amigdalin:-
에리스리톨 : -Erythritol:-
에스큘린 : +Esculin: +
유당 : +Lactose: +
이눌린 : -Inulin:-
자당 : +Sucrose: +
전분 : +Starch: +
크실로스 : +Xylose: +
트레할로스 : -Trehalose:-
포도당 : +Glucose: +
이상과 같이, 비피도박테리움 롱검 HS90 균주는 호기적으로 성장하지 못하고, 그람 양성, 카탈리제 음성, F6PPK 양성이며, 아도니톨, 두시톨, 에리스리톨, 글리세롤, 람노스, 소르보스로부터 산을 생성하지 않으며, 유산과 초산을 1.56 : 1 로 생산하고, 현미경상으로 간균, Y자, 곤봉형태를 나타내므로, 본 발명에 따른 신균주는 비피도박테리움 속의 유산균임이 인정되었다.As described above, the Bifidobacterium longgum HS90 strain does not grow aerobically, is Gram positive, catalase negative, F6PPK positive, and generates acid from adonitol, ducitol, erythritol, glycerol, rhamnose, and sorbose. Since lactic acid and acetic acid are produced in 1.56: 1, and microscopically shows bacilli, Y-shaped, and club-like shapes, the new strain according to the present invention was recognized as lactic acid bacteria in Bifidobacterium.
본 발명에 따른 비피도박테리움 롱검 HS90은 12% 탈지유, 비엘 배지에서 양호하게 생육되었으며, 비피도박테리움 속의 일반적인 균주와 달리 다량의 점질다당류를 생산하였다.Bifidobacterium longgum HS90 according to the present invention was well grown in 12% skim milk, BELL medium, and produced a large amount of viscous polysaccharides unlike general strains of Bifidobacterium spp.
이하, 본 발명을 다음의 비제한적인 실시예를 통해 보다 상세하게 설명한다.Hereinafter, the present invention will be described in more detail with reference to the following non-limiting examples.
[실시예 1]Example 1
[균주 분리][Strain separation]
건강한 유아의 분변을 배변 즉시 채취하여 유동 파라핀이 중층된 비엘 액체배지에 넣어 실험실로 이송하였다. 시료를 혐기 희석액으로 희석하여 엔피엔엘 한천 평판배지에 0.1ml 도말한 후 혐기자에 넣고 이산화탄소로 차환한 후 37℃에서 48시간 배양하였다.The feces of healthy infants were immediately collected for defecation and transferred to a laboratory in fluid paraffin-laminated Biel liquid medium. The sample was diluted with an anaerobic dilution solution, plated in 0.1 ml plate of NPEL agar, and then put in an anaerobic fertilizer and incubated at 37 ° C. for 48 hours.
엔피엔엘 한천배지상에 나타난 균락을 백금이로 접촉하여 끈적거리는 균락을 점성물질 생성균주로 선발·분리하였다. 순수 분리된 균주는 비엘 배지에서 37℃로 24시간 배양한 후 0.2%의 효모 추출물이 함유된 12% 멸균 한천 탈지유에 재접종하여 37℃에서 24시간 배양하고, 배양액의 점성 유무를 확인하였다. 분리된 새로운 균주는 일반 비피도박테리아의 3~10배에 해당하는 1142mg/ml의 다량의 다당류를 생산하였다.The cracks on the NEP agar medium were contacted with platinum, and the sticky cracks were selected and separated as viscous substance-generating strains. Purely isolated strains were incubated at 37 ° C. for 24 hours in Biel medium, and then re-inoculated with 12% sterile agar skim milk containing 0.2% yeast extract, and cultured at 37 ° C. for 24 hours, and the presence of viscous culture medium was confirmed. The isolated new strain produced a large amount of polysaccharides of 1142 mg / ml, which is 3 to 10 times the normal Bifidobacteria.
이에 사용된 비엘배지와 엔피엔엘 한천배지의 조성은 다음과 같다.The composition of BIEL and ENP Agar medium used for this is as follows.
* 비엘 배지의 조성* Composition of Biel Medium
염화시스테인 0.5g0.5 g of cysteine chloride
포도당 10 g10 g of glucose
육추추물 3gJujube Extract 3g
간추출물 용액1)150mlLiver extract solution 1) 150ml
파이톤(phyton, BBL) 3gPhyton (BBL) 3g
피로테오스 펩톤 No.3 10gPyoteose Peptone No.3 10g
용액 A2)10mlSolution A 2) 10ml
용액 B3)5mlSolution B 3) 5ml
전분(수용성) 0.5gStarch (aqueous) 0.5g
트윈 80(tween 80) 1gTween 80 1 g
트립톤(tryton) 5gTryton 5g
효모추출물 5g5g yeast extract
증류수 815mlDistilled Water 815ml
1) 간 추출물 용액 : 10g의 간 분말을 170ml의 증류수에 넣고 50~60℃의 온도에서 1시간동안 정치시킨 후 10분간 끓인 다음 거름종이로 걸러낸다.1) Liver extract solution: Put 10g liver powder in 170ml of distilled water, let stand for 1 hour at 50 ~ 60 ℃, boil for 10 minutes and filter it with filter paper.
2) 용액 A :2) Solution A:
인산칼륨(monobasic) 25g25 g of potassium phosphate (monobasic)
인산칼륨(dibasic) 25g25 g of potassium diphosphate
증류수 250ml250ml of distilled water
3) 용액 B :3) Solution B:
황산철(FESO4·7H2O) 0.5g0.5 g of iron sulfate (FESO 4 · 7H 2 O)
황산마그네슘(MgSO4·7H2O) 10g10 g of magnesium sulfate (MgSO 4 .7H 2 O)
황산망간(MnSO4·4H2O) 0.33g0.33 g of manganese sulfate (MnSO 4 4H 2 O)
염화나트륨 0.5g0.5 g sodium chloride
증류수 250ml250ml of distilled water
*엔피엔엘 한천배지* ENP & L Agar Badge
비엘배지 100mlBiel Badge 100ml
한천 1.5gAgar 1.5g
엔피엔엘 용액1)5mlNP & L solution 1) 5ml
1)엔피엔엘 용액1) nP & L solution
염화리튬(LiCl) 6g6 g of lithium chloride (LiCl)
날리딕산(nalidixic acid) 0.03gNalidixic acid 0.03 g
황산네오마이신 0.2g0.2 g neomycin sulfate
파로모마이신 0.4gParomomycin 0.4 g
증류수 100ml100ml of distilled water
[실시예 2]Example 2
[탈지유 배양액의 점도][Viscosity of skim milk culture solution]
12% 환원 탈지유에 0.2% 효모 추출물을 첨가하여 멸균한 배지에, 본 균주 비피도박테리움 롱검 HS90과 점성물질을 생산하지 않는 비피도박테리아 균주(M)를 각각 1% 접종하여 37℃에서 pH 4.5까지 배양한 후 배양액의 점도를 측정하였다. 그 결과 전단속도에 따른 점도의 변화를 제1도에 나타내었다.To the sterilized medium by adding 0.2% yeast extract to 12% reduced skim milk, 1% of the strain Bifidobacterium longgum HS90 and Bifidobacteria strain (M) which does not produce a viscous substance were inoculated 1% and pH 4.5 at 37 ° C. After culturing until the viscosity of the culture was measured. As a result, the change in viscosity according to the shear rate is shown in FIG.
제1도로부터 본 발명에 따른 비피도박테리움 롱검 HS90이 다량의 점질다당류를 생산함으로써 배양시 배양액의 점도가 일반 비피도박테리아에 비해 훨씬 높아진다는 것을 확인할 수 있었다.It can be seen from FIG. 1 that the Bifidobacterium longgum HS90 according to the present invention produced a large amount of viscous polysaccharides, which resulted in a much higher viscosity of the culture medium than that of the normal Bifidobacteria.
[실시예 3]Example 3
[탈지유 배양액의 유청분리도 검사][Whey Separation Test of skim milk culture]
12% 환원 탈지유에 0.2% 효모 추출물을 첨가하여 멸균한 배지에, 본 균주 비피도박테리움 롱검 HS90과 점성물질을 생산하지 않는 균주(M)를 각각 1% 접종하여 37℃에서 pH 4.5까지 배양한 후 배양액을 원심분리하여 유청분리의 정도를 측정하였다. 그 결과 원심력에 따른 유청분리 정도를 제2도에 나타내었다.Inoculated 1% of strain Bifidobacterium longgum HS90 and strain (M) which do not produce a viscous substance, respectively, in sterilized medium by adding 0.2% yeast extract to 12% reduced skim milk and incubated to pH 4.5 at 37 ° C. The culture was then centrifuged to determine the degree of whey separation. As a result, the degree of whey separation according to the centrifugal force is shown in FIG.
제2도로부터 본 발명에 따른 비피도박테리움 롱검 HS90을 발효균주로 사용할 경우 발효유의 유청분리현상이 크게 완화된다는 것을 확인할 수 있었다.2 shows that whey separation of fermented milk is greatly alleviated when Bifidobacterium longgum HS90 according to the present invention is used as a fermentation strain.
[실시예 4]Example 4
[배양온도에 따른 유청분리도 검사][Whey Separation Test by Culture Temperature]
12% 환원 탈지유에 0.2% 효모 추출물을 첨가하여 멸균한 배지에, 점성물질을 생산하는 본 균주 비피도박테리움 롱검 HS90을 1% 접종하여 32℃, 37℃, 40℃에서 pH 4.5까지 각각 배양한 후 배양액을 원심분리하여 유청분리 정도를 측정하였다. 그 결과, 원심력에 따른 유청분리 정도를 제3도에 나타내었다.1% of Bifidobacterium longgum HS90, which produces viscous substances, was inoculated into a sterilized medium by adding 0.2% yeast extract to 12% reduced skim milk, and incubated to pH 4.5 at 32 ° C, 37 ° C and 40 ° C, respectively. After the culture was centrifuged to determine the degree of whey separation. As a result, the degree of whey separation according to the centrifugal force is shown in FIG.
[실시예 5]Example 5
[피부 전기전도도 측정 검사][Skin conductivity test]
본 균주가 생산하는 점질다당류를 분리하여 피부에 대한 보습 효과를 알아보기 위해 피부에 도포한 후 전기 전도도를 측정하고, 이를 정제수 및 히야론산과 비교하여 그 결과를 다음의 표1에 나타내었다.To isolate the viscous polysaccharides produced by this strain to determine the moisturizing effect on the skin and to measure the electrical conductivity, and compared with purified water and hyaluronic acid, the results are shown in Table 1 below.
상기 표 1로부터 알 수 있는 바와 같이, 비피도박테리움 롱검 HS90이 생산하는 점질다당류는 히야론산과 대등한 우수한 피부보습효과를 나타낸다.As can be seen from Table 1, the viscous polysaccharide produced by Bifidobacterium long gum HS90 exhibits an excellent skin moisturizing effect comparable to that of hyaluronic acid.
상기 실시예로부터 알 수 있는 바와 같이, 본 발명에 따른 새로운 유산균인 비피도박테리움 롱검 HS90은 다량의 점질다당류를 생산하므로 본 균주를 발효균주로 사용하여 발효유를 제조할 경우 발효유의 점도를 높여주고 조직을 부드럽게 하여 유청분리가 없는 농후한 외관(body)의 질좋은 발효유를 얻을 수 있으며, 또한 본 균주는 보습성이 좋은 점질다당류를 생산하므로 이를 분리하여 화장품의 보습제 및 식품의 안정제 등으로 이용할 수 있다.As can be seen from the above embodiment, the new lactic acid bacteria Bifidobacterium longgum HS90 according to the present invention produces a large amount of viscous polysaccharides, thus increasing the viscosity of the fermented milk when preparing the fermented milk using the strain as a fermentation strain. It can be used to obtain high quality fermented milk with body without whey separation. In addition, this strain produces viscous polysaccharides with good moisturizing properties, so it can be separated and used as a moisturizer for food and stabilizer of food. .
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019950027604A KR0158049B1 (en) | 1995-08-30 | 1995-08-30 | Novel bifidobacterium longum hspo which produce polysaccharide |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019950027604A KR0158049B1 (en) | 1995-08-30 | 1995-08-30 | Novel bifidobacterium longum hspo which produce polysaccharide |
Publications (2)
Publication Number | Publication Date |
---|---|
KR970010960A KR970010960A (en) | 1997-03-27 |
KR0158049B1 true KR0158049B1 (en) | 1998-11-16 |
Family
ID=19425197
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019950027604A KR0158049B1 (en) | 1995-08-30 | 1995-08-30 | Novel bifidobacterium longum hspo which produce polysaccharide |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR0158049B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150109648A (en) * | 2014-03-20 | 2015-10-02 | 강원대학교산학협력단 | Cheunggukjang Using Lactobacillus acidophilus(KCTC 3925) or Lactobacillus rhamnosus (KCTC 3929) with Increased Isoflavones and Exopolysaccharides and the Method of Making the Same |
-
1995
- 1995-08-30 KR KR1019950027604A patent/KR0158049B1/en active IP Right Grant
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150109648A (en) * | 2014-03-20 | 2015-10-02 | 강원대학교산학협력단 | Cheunggukjang Using Lactobacillus acidophilus(KCTC 3925) or Lactobacillus rhamnosus (KCTC 3929) with Increased Isoflavones and Exopolysaccharides and the Method of Making the Same |
Also Published As
Publication number | Publication date |
---|---|
KR970010960A (en) | 1997-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
van Geel-Schutten et al. | Screening and characterization of Lactobacillus strains producing large amounts of exopolysaccharides | |
Van Den Berg et al. | Production of a novel extracellular polysaccharide by Lactobacillus sake 0-1 and characterization of the polysaccharide | |
Pintado et al. | Microbiological and rheological studies on Portuguese kefir grains | |
Bouzar et al. | Exopolysaccharide production and texture-promoting abilities of mixed-strain starter cultures in yogurt production | |
US4797278A (en) | Hypocholesterolemically and/or hypotriglyceridemically active products and their use | |
EP1282687A1 (en) | Microorganisms for treatment or prevention of obesity and diabetes mellitus, and pharmaceutical composition containing the same | |
KR100471631B1 (en) | Bifidobacterium breve and fermented soymilk prepared with the same | |
US4588595A (en) | Culture containing a viable cell mass of Bifidobacteria and lactic acid bacteria | |
Roach et al. | Lactobacilli isolated from the stomach of conventional mice | |
RU2418857C2 (en) | Polysaccharide produced by microorganism, belonging to genus bifidobacterium | |
Ludbrook et al. | Exopolysaccharide production from lactic acid bacteria isolated from fermented foods | |
KR0158049B1 (en) | Novel bifidobacterium longum hspo which produce polysaccharide | |
EP0112020B2 (en) | A new microorganism belonging to streptococcus thermophilus and a composition containing said microorganism | |
KR100299306B1 (en) | Lactic acid bacteria with high acid resistance and growth rate and excellent blood cholesterol lowering ability | |
JP3444508B2 (en) | Novel bifidobacterium strain and method for producing fermented milk using the same | |
Rada | Effect of Kluyveromyces marxianus on the growth and survival of bifidobacteria in milk | |
RU2506308C1 (en) | CONSORTIUM OF PROBIOTIC STRAINS OF Lactobacillus rhamnosus AND Lactobacillus plantarum FOR PRODUCING BACTERIAL PREPARATION AND DIRECT ADMINISTRATION FERMENT FOR PRODUCING FERMENTED MILK AND FERMENTED BEET JUICE | |
El-Shafei et al. | Production of high quality functional Labneh cheese using exopolysaccharides producing encapsulated Lactobacillus bulgaricus | |
KR0142615B1 (en) | New Lactic Acid Bacteria with Excellent Acid Resistance and Cholesterol Degradation Isolated from Feces of Korean Infant and Their Use | |
JP5420153B2 (en) | Method for producing aldonic acid by lactic acid bacteria | |
KR0157757B1 (en) | Separation method for bifidobacterium which has acid tolerance | |
RU2295563C1 (en) | Bacterium strain lactococcus lactis subcpecies lactis b-8558 useful in dairy product preparation and method for production of starter culture of strain lactococcus lactis subcpecies lactis b-8558 | |
JPS5953829B2 (en) | A novel microorganism belonging to Bifidobacterium longum, a method for producing the microorganism, and a composition containing the microorganism | |
JP2627698B2 (en) | Culture containing live cells of Bifidobacterium breve and method for producing the same | |
RU2115724C1 (en) | Strain of bacterium streptococcus lactis - a producer of nisin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20060801 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20070802 Year of fee payment: 17 |